Born on November 10, 1982, Dr. Xiaoying Wang completed her undergraduate studies at Bengbu Medical College in 2004. She obtained her Master's degree from Nanjing Medical University in 2012 and subsequently enrolled in Southeast University. In 2014, she received funding from the China Scholarship Council to pursue joint doctoral studies at Yale University, returning to China in 2016 and graduating with a Doctor of Medicine degree from Southeast University in June of the same year. During her doctoral studies, she published 4 SCI papers and secured funding from the Jiangsu Graduate Innovation Fund. Key Publications: 1. Xiaoying Wang,Xiangfeng He,Fengshu Zhao, et al. Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis. Journal of Translational Medicine, 2014. 2. Xiaoying Wang,Xiangfeng He,Fengshu Zhao, et al. Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine. Oncotarget, 2015. 3. Xiaoying Wang,Xiangfeng He, Fengshu Zhao, et al. Reinforce of B16F10/GPI-IL-21 vaccine against melanoma efficacy via adminsistration of miR200c agomir and shZEB1 plasmid in mice, Biomedicine & Pharmacotherapy, 2016. 4. Xiaoying Wang,Jiangbing Zhou, et al. Hypouricemic and Nephroprotective Effects of AS1202 in a Rat Model of hyperuricemia. International Journal of Clinical and Experimental Medicine,2016. |
